Accenture, a global management consulting, technology services and outsourcing provider, has announced that it launched Predictive Health Intelligence, a set of cloud-based data analytics to help life sciences companies deliver better medical treatment.
“By combining Accenture’s extensive experience in life sciences and health care with the most advanced cloud technologies and data science capabilities, we have built a set of innovative solutions that provides our clients with a deeper understanding of all facets of patient care,” said Anne O’Riordan, global industry managing director for Accenture’s Life Sciences practice. “With this deeper understanding, companies can take specific actions to raise the quality of care, improve care coordination and apply this approach over a longer period than a single moment of care. These are all key priorities for the industry.”
With Predictive Health Intelligence, doctors, patients, insurance companies, pharmaceutical companies, hospitals and others will be able to aggregate data and use it to deliver better care by identifying gaps in care and fixing them. It will also inform research into areas of healthcare, delivering new treatments. All of this will be done in real time using cloud-based analytics.
Accenture has turned to a number of partners, including Explorys, providers of the big data analytics platform; Liaison Technologies, which is integrating the data using a big data technology platform and Predixion software which is handling the analytics.
Accenture is betting that all of the stakeholders in healthcare, including pharmaceutical companies, will see more value in improving patient outcomes.
“Life sciences companies are striving to become value-centric organizations, focusing on improving the health outcomes of individual patients and populations,” said Jeffrey Russell, senior managing director of Accenture’s Life Sciences North America practice. “We have already started to deliver services on behalf of a large global pharmaceutical company where we are aggregating data to perform observational studies to measure the value, usage, and effectiveness of drug therapies.”
Edited by
Stefania Viscusi
